Wuhan Guanggu humanwell class 1.1 analgesic meisuoshuli obtained clinical approval

Humanwell pharmaceutical announced in the evening of June 23 that the company's joint-stock subsidiary, Wuhan Optics Valley humanwell, had obtained the clinical approval documents for the 1.1-class chemical drug mesuosuli and two specifications of mesuosuli film coated tablets (50mg / 100mg), and could carry out phase I clinical trials At present, there are no other domestic enterprises applying for the product Meisuoshuli has anti-inflammatory, analgesic and antipyretic effects It is mainly used in the treatment of rheumatoid arthritis, osteoarthritis and other chronic arthritis It can also be used in surgery and acute post-traumatic pain and inflammation, otorhinopharyngeal inflammation, menstrual pain and other pain It can also be used in upper respiratory tract infection caused by fever and other diseases Compared with similar foreign drugs, it has It has the advantages of good curative effect and low side effects Humanwell pharmaceutical is mainly engaged in the pharmaceutical industry, and its market segments include anesthetics, analgesics, birth control drugs, blood products, Uyghur ethnic medicine, etc At present, humanwell holds 32.52% of the equity of Optics Valley humanwell, which is the largest shareholder of humanwell.